{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T11:46:25Z","timestamp":1785757585555,"version":"3.56.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T00:00:00Z","timestamp":1771545600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100019155","name":"Nanjing Drum Tower Hospital","doi-asserted-by":"publisher","award":["2025-0895-02"],"award-info":[{"award-number":["2025-0895-02"]}],"id":[{"id":"10.13039\/501100019155","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.ijantimicag.2026.107749","type":"journal-article","created":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T00:24:29Z","timestamp":1771633469000},"page":"107749","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Omeprazole is associated with voriconazole-associated hepatotoxicity: PPI-stratified analysis and a clinically actionable nomogram from an 848-patient cohort"],"prefix":"10.1016","volume":"67","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-7536-7436","authenticated-orcid":false,"given":"Yuhang","family":"Ding","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanhong","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huaijun","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7723-3740","authenticated-orcid":false,"given":"Qiuhui","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2026.107749_bib0001","doi-asserted-by":"crossref","first-page":"e428","DOI":"10.1016\/S1473-3099(23)00692-8","article-title":"Global incidence and mortality of severe fungal disease","volume":"24","author":"Denning","year":"2024","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijantimicag.2026.107749_bib0002","doi-asserted-by":"crossref","first-page":"ofab593","DOI":"10.1093\/ofid\/ofab593","article-title":"Prevalence and healthcare burden of fungal infections in the United States, 2018","volume":"9","author":"Rayens","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.ijantimicag.2026.107749_bib0003","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/ciw326","article-title":"Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 update by the Infectious Diseases Society of America","volume":"63","author":"Patterson","year":"2016","journal-title":"Clinical Infectious Diseases"},{"key":"10.1016\/j.ijantimicag.2026.107749_bib0004","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1086\/596757","article-title":"Clinical Practice Guidelines for the Management Candidiasis: 2009 update by the Infectious Diseases Society of America","volume":"48","author":"Pappas","year":"2009","journal-title":"Clinical Infectious Diseases"},{"key":"10.1016\/j.ijantimicag.2026.107749_bib0005","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1097\/FTD.0000000000000561","article-title":"Individualized medication of Voriconazole: a practice guideline of the Division of Therapeutic Drug Monitoring, Chinese Pharmacological Society","volume":"40","author":"Chen","year":"2018","journal-title":"Therap Drug Monitoring"},{"key":"10.1016\/j.ijantimicag.2026.107749_bib0006","doi-asserted-by":"crossref","first-page":"649","DOI":"10.2165\/00003088-200645070-00002","article-title":"Pharmacokinetic\/pharmacodynamic profile of voriconazole","volume":"45","author":"Theuretzbacher","year":"2006","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.ijantimicag.2026.107749_bib0007","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1093\/cid\/cis599","article-title":"The effect of therapeutic drug monitoring on safety and efficacy of voriconazole in invasive fungal infections: a randomized controlled trial","volume":"55","author":"Park","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2026.107749_bib0008","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1111\/myc.13293","article-title":"The influence of CYP2C19 polymorphisms on voriconazole trough concentrations: systematic review and meta-analysis","volume":"64","author":"Zhang","year":"2021","journal-title":"Mycoses"},{"key":"10.1016\/j.ijantimicag.2026.107749_bib0009","series-title":"Medical Genetics Summaries","article-title":"Voriconazole therapy and CYP2C19 genotype","author":"Dean","year":"2012"},{"key":"10.1016\/j.ijantimicag.2026.107749_bib0010","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/cpt.583","article-title":"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C19 and Voriconazole therapy","volume":"102","author":"Moriyama","year":"2017","journal-title":"Clin Pharma Therap"},{"key":"10.1016\/j.ijantimicag.2026.107749_bib0011","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1016\/j.clinthera.2022.10.005","article-title":"Clinical Practice Guideline for the Therapeutic Drug Monitoring of voriconazole in Non-Asian and Asian adult patients: consensus Review by the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring","volume":"44","author":"Takesue","year":"2022","journal-title":"Clin Therap"},{"key":"10.1016\/j.ijantimicag.2026.107749_bib0012","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1093\/jac\/dkw045","article-title":"Trough concentration of voriconazole and its relationship with efficacy and safety: a systematic review and meta-analysis","volume":"71","author":"Jin","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2026.107749_bib0013","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.ijantimicag.2014.05.019","article-title":"Voriconazole pharmacokinetics and exposure\u2013response relationships: assessing the links between exposure, efficacy and toxicity","volume":"44","author":"Dolton","year":"2014","journal-title":"Int JAntimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2026.107749_bib0014","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.19851","article-title":"Agreement of different drug-drug interaction checkers for proton pump inhibitors","volume":"7","author":"Carollo","year":"2024","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.ijantimicag.2026.107749_bib0015","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1111\/bcp.14267","article-title":"A multicentre prospective study evaluating the impact of proton-pump inhibitors omeprazole and pantoprazole on voriconazole plasma concentrations","volume":"86","author":"Blanco Dorado","year":"2020","journal-title":"Brit J Clinical Pharma"},{"key":"10.1016\/j.ijantimicag.2026.107749_bib0016","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.ijantimicag.2016.11.025","article-title":"Influence of different proton pump inhibitors on the pharmacokinetics of voriconazole","volume":"49","author":"Qi","year":"2017","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2026.107749_bib0017","doi-asserted-by":"crossref","first-page":"5166","DOI":"10.1111\/bcp.15495","article-title":"Effects of inflammation on voriconazole levels: a systematic review","volume":"88","author":"Li","year":"2022","journal-title":"Brit J Clin Pharma"},{"key":"10.1016\/j.ijantimicag.2026.107749_bib0018","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1128\/AAC.02830-15","article-title":"Longitudinal analysis of the effect of inflammation on voriconazole trough concentrations","volume":"60","author":"Encalada Ventura","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2026.107749_bib0019","series-title":"Resources for Researchers: Common Terminology Criteria for Adverse Events (CTCAE)","year":"2018"},{"key":"10.1016\/j.ijantimicag.2026.107749_bib0020","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1002\/phar.1779","article-title":"Risk factors for voriconazole-associated hepatotoxicity in patients in the intensive care unit","volume":"36","author":"Wang","year":"2016","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ijantimicag.2026.107749_bib0021","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1007\/s15010-012-0322-x","article-title":"Efficacy and safety of voriconazole in the treatment of chronic pulmonary aspergillosis: experience in Japan","volume":"40","author":"Pulmonary Fungosis Research Group","year":"2012","journal-title":"Infection"},{"key":"10.1016\/j.ijantimicag.2026.107749_bib0022","doi-asserted-by":"crossref","unstructured":"Shen K., Gu Y., Wang Y., Lu Y., Ni Y., Zhong H., et al. Therapeutic drug monitoring and safety evaluation of voriconazole in the treatment of pulmonary fungal diseases. Drug Safety n.d.;13.","DOI":"10.1177\/20420986221127503"},{"key":"10.1016\/j.ijantimicag.2026.107749_bib0023","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s12879-025-10459-8","article-title":"Safety and recommendation of voriconazole for invasive pulmonary aspergillosis in severe liver disease patients: a retrospective cohort study","volume":"25","author":"Zhang","year":"2025","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.ijantimicag.2026.107749_bib0024","doi-asserted-by":"crossref","first-page":"7475","DOI":"10.2147\/IDR.S391022","article-title":"Central nervous system toxicity of voriconazole: risk factors and threshold \u2013 a retrospective cohort study","volume":"15","author":"Yang","year":"2022","journal-title":"IDR"},{"key":"10.1016\/j.ijantimicag.2026.107749_bib0025","doi-asserted-by":"crossref","first-page":"3617","DOI":"10.2147\/DDDT.S475706","article-title":"The role of plasma trough concentration of voriconazole and voriconazole N-oxide in its hepatotoxicity in adult patients","volume":"18","author":"Cheng","year":"2024","journal-title":"DDDT"},{"key":"10.1016\/j.ijantimicag.2026.107749_bib0026","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.3390\/genes11121509","article-title":"Distinct effects of inflammation on cytochrome P450 regulation and drug metabolism: lessons from experimental models and a potential role for pharmacogenetics","volume":"11","author":"De Jong","year":"2020","journal-title":"Genes"},{"key":"10.1016\/j.ijantimicag.2026.107749_bib0027","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1002\/cpt.2146","article-title":"Impact of acute inflammation on cytochromes P450 activity assessed by the Geneva cocktail","volume":"109","author":"Lenoir","year":"2021","journal-title":"Clin Pharma Therap"},{"key":"10.1016\/j.ijantimicag.2026.107749_bib0028","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1124\/dmd.107.018747","article-title":"Regulation of drug-metabolizing enzymes and transporters in infection, inflammation, and cancer","volume":"36","author":"Morgan","year":"2008","journal-title":"Drug Metab Disposition"},{"key":"10.1016\/j.ijantimicag.2026.107749_bib0029","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/jac\/dkw349","article-title":"Voriconazole metabolism is influenced by severe inflammation: a prospective study","volume":"72","author":"Veringa","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2026.107749_bib0030","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1097\/INF.0000000000003898","article-title":"Boosting of voriconazole levels with omeprazole, A CYP450 2C19 inhibitor","volume":"42","author":"Hsu","year":"2023","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.ijantimicag.2026.107749_bib0031","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00207-21","article-title":"Impact of CYP2C19 phenotype and drug-drug interactions on voriconazole concentration in pediatric patients","volume":"65","author":"Tian","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2026.107749_bib0032","doi-asserted-by":"crossref","unstructured":"Li X. Notable drug-drug interaction between omeprazole and voriconazole in CYP2C19 *1 and *2 (rs4244285, 681G>A) alleles in vitro n.d. https:\/\/pubmed.ncbi.nlm.nih.gov\/39445918\/(accessed November 5, 2025).","DOI":"10.1080\/00498254.2024.2421513"},{"key":"10.1016\/j.ijantimicag.2026.107749_bib0033","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jiac.2020.11.014","article-title":"Optimal trough concentration of voriconazole with therapeutic drug monitoring in children: a systematic review and meta-analysis","volume":"27","author":"Hanai","year":"2021","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.ijantimicag.2026.107749_bib0034","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2019.106078","article-title":"Therapeutic drug monitoring and safety of voriconazole in elderly patients","volume":"78","author":"Cheng","year":"2020","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.ijantimicag.2026.107749_bib0035","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1439586","article-title":"Voriconazole: a review of adjustment programs guided by therapeutic drug monitoring","volume":"15","author":"Jiang","year":"2024","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.ijantimicag.2026.107749_bib0036","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2022.106692","article-title":"Voriconazole therapeutic drug monitoring and hepatotoxicity in critically ill patients: a nationwide multi-centre retrospective study","volume":"60","author":"Wang","year":"2022","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2026.107749_bib0037","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1177\/0272989X06295361","article-title":"Decision curve analysis: a novel method for evaluating prediction models","volume":"26","author":"Vickers","year":"2006","journal-title":"Med Decis Making"},{"key":"10.1016\/j.ijantimicag.2026.107749_bib0038","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.g7594","article-title":"Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement","volume":"350","author":"Collins","year":"2015","journal-title":"BMJ"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857926000385?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857926000385?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T11:04:01Z","timestamp":1785755041000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857926000385"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":38,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S0924857926000385"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2026.107749","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Omeprazole is associated with voriconazole-associated hepatotoxicity: PPI-stratified analysis and a clinically actionable nomogram from an 848-patient cohort","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2026.107749","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"107749"}}